Avalo Reports 2022 Financial Results and Provides Business Updates
Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline…
Month: March 2023
Avalo Reports 2022 Financial Results and Provides Business Updates
Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline…
PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium
FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium
FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase…
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase…
PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease
TORONTO, March 29, 2023 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB:…
PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease
TORONTO, March 29, 2023 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB:…
TELA Bio’s OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023
Presentations highlight utility of this advanced hernia reinforcement material for robotic procedures MALVERN, Pa., March…
TELA Bio’s OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023
Presentations highlight utility of this advanced hernia reinforcement material for robotic procedures MALVERN, Pa., March…
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
BOSTON, March 29, 2023 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company…
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
BOSTON, March 29, 2023 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company…
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
Complete elimination of viral load in 100% of patients at day 7 vs 6% in…
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
Complete elimination of viral load in 100% of patients at day 7 vs 6% in…
Breckenridge Distillery Establishes March 31st as National Après Day
The World’s Highest Distillery Launches First Ever National Après Day in the U.S. and Celebrates #AprèsAnywhere…
Breckenridge Distillery Establishes March 31st as National Après Day
The World’s Highest Distillery Launches First Ever National Après Day in the U.S. and Celebrates #AprèsAnywhere…
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed…
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed…
BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment…
BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment…